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Abstract
Angiogenesis is a fundamental vertebrate developmental process that requires signalling by
the secreted protein vascular endothelial growth factor-A (VEGF-A). VEGF-A functions in
the development of embryonic structures, during tissue remodelling and for the growth of
tumour-induced vasculature. The study of the role of VEGF-A during normal development
has been signi®cantly complicated by the dominant, haplo-insuf®cient nature of VEGF-A-
targeted mutations in mice. We have used morpholino-based targeted gene knock-down
technology to generate a zebra®sh VEGF-A morphant loss of function model. Zebra®sh
VEGF-A morphant embryos develop with an enlarged pericardium and with major blood
vessel de®ciencies. Morphological assessment at 2 days of development indicates a nearly
complete absence of both axial and intersegmental vasculature, with no or reduced
numbers of circulating red blood cells. Molecular analysis using the endothelial markers
¯i-1 and ¯k-1 at 1 day of development demonstrates a fundamental distinction between
VEGF-A requirements for axial and intersegmental vascular structure speci®cation.
VEGF-A is not required for the initial establishment of axial vasculature patterning,
whereas all development of intersegmental vasculature is dependent on VEGF-A signalling.
The zebra®sh thus serves as a quality model for the study of conserved vertebrate
angiogenesis processes during embryonic development. Copyright # 2000 John Wiley &
Sons, Ltd.
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Introduction
Signalling by members of the vascular endothelial
growth factor (VEGF) gene family is implicated in
the formation of vasculature during embryogenesis,
during wound healing and for the growth of
tumour-induced vasculature (for reviews, see Car-
meliet and Collen, 1997; Ferrara, 1999). Pioneering
work in mice with VEGF-A demonstrates the
extreme dose responsiveness of the mouse embryo
to VEGF-A signalling during development. Loss of
a single copy of the VEGF-A gene induces haplo-
insuf®cient lethality by day 9.5 pc (Ferrara et al.,
1996; Carmeliet et al., 1996). This biological hurdle
to the genetic investigation of VEGF-A require-
ments during later development has resulted in a
series of experiments using conditional knock-out
strategies (Gerber et al., 1999; Haigh et al., 2000) or
dominant negative proteins (Gerber et al., 1999). A
more recent approach to address this problem used
intravenous injection of antisense oligonucleotides
in pregnant mice to reveal loss of function require-
ments of VEGF-A function during murine embry-
ogenesis (Driver et al., 1999).
Yeast
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only limited requirements for a functioning circula-
tory system during early development. For example,
embryos with no circulating red blood cells due to
porphyria live through the ®rst 3 days of develop-
ment (Ransom et al., 1996), a time period which
includes all of segmentation and organogenesis in
the ®sh embryo. Multiple mutations in cardiovas-
cular development were isolated in the initial large-
scale chemical mutagenesis screens (Stainier et al.,
1996; Chen et al., 1996; Weinstein et al., 1995). The
zebra®sh has the potential to rapidly assess the
biological role of angiogenic factors required for
this essential vertebrate process.
We used morpholino-based oligonucleotides
(morpholinos, MO; Summerton, 1999) to create
a VEGF-A loss of function developmental model
to circumvent potential haplo-insuf®cient genetic
complications in zebra®sh. These VEGF-A mor-
phant embryos display an enlarged pericardium
and a modest body size decrease and have severe
de®ciencies in vascular development. We show
that the establishment of the axial and inter-
segmental vasculature has distinct requirements
for VEGF-A signalling, as revealed by analysis of
the expression of two endothelial markers, the
tyrosine kinase VEGF receptor, ¯k-1 (Sumoy et al.,
1997; Fouquet et al., 1997; Thompson et al.,
1998) and the early vascular marker, the tran-
scription factor ¯i-1 (Thompson et al., 1998;
Brown et al., 2000). Initial axial expression of
these markers is not altered in VEGF-A morphant
embryos, while no intersegmental expression of
these markers is detected. Both axial and inter-
segmental vasculature fail to function in VEGF-A
morphant embryos, however, indicating a role for
VEGF-A beyond the establishment of ¯k-1 and ¯i-
1 expression in blood vessel formation. Similar
phenotypes were observed in some mutations
found in chemical mutagenesis screens, suggesting
a possible role for these genes in VEGF-A
signalling in the zebra®sh embryo.
Materials and methods
Morpholino injections
Morpholino antisense oligonucleotides were pur-
chased from Gene-Tools, LLC (Corvallis, OR).
Solutions were prepared and injected as described
in Nasevicius and Ekker (2000): VEGF-A-1 (pre-






Microangiography was performed similarly to the
method described in Weinstein et al. (1995).
Fluorescein isothiocyanate±Dextran (FITC±Dex-
tran) with a molecular weight of 2 000 000 Da
(SIGMA, catalogue #FD-2000S) was used for
these studies. The Dextran was solubilized in
1rDanieau solution (58 mM NaCl, 0.7 mM KCl,
0.4 mM MgSO4, 0.6 mM Ca(NO3)2,5 m M HEPES,
pH 7.6) at 2 mg/ml concentration. 10 ml of the
prepared solution was injected into the sinus
venosa/cardinal vein of the anaesthetized 48 h
embryo. The visualization and photography was
performed on a ZEISS Axioskop 2 microscope
using a standard FITC ®lter set.
Red blood cell (RBC) ¯uorescence
visualization in urod morpholino-injected
embryos
The ¯uorescence of red blood cells was observed
and photographed as described in Nasevicius and
Ekker (2000).
RNA localization
Whole mount in situ hybridization was performed
as described in Jowett (1999). Hybridization was
performed at 65uC. Riboprobes for ¯i-1 and ¯k-1
were synthesized using plasmids zf¯i-1 and zf¯k-1
(Thompson et al., 1998), digested with EcoRI and
SmaI, respectively. T7 polymerase was used for
riboprobe synthesis.
Tissue sectioning and visualization
Embryos with FITC±Dextran visualized vascula-
ture were ®xed overnight, embedded into paraf®n
using standard procedures, and sectioned. FITC±
Dextran ¯uorescence outlining blood vessels in
unprocessed tissue sections was visualized using
ZEISS Axioskop 2 microscope with a FITC ®lter
set. Histological haematoxylin±eosin staining of the
sections was subsequently carried out using a
standard protocol.
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Bright-®eld and in situ photography was performed
on a ZEISS Axioplan 2 microscope using Nikon
CoolPix 990 (bright-®eld) or Kodak DCS 420 (in
situ) digital cameras. For ¯uorescent photography,
a ZEISS AxioCam or a Nikon CoolPix 990 digital
camera was used.
Results and discussion
Zebra®sh VEGF-A is expressed during embryogen-
esis in the anterior nervous system, in mesoderm
¯anking the prospective heart ®elds, and in somitic
mesoderm that ¯anks the developing endoderm
(Liang et al., 1998). We generated morpholino
(Summerton, 1999) antisense oligonucleotides
against VEGF-A to analyse the requirements of
this gene during embryonic development. Morpho-
linos have been recently shown to be effective at
gene inactivation during the ®rst 2 days of zebra®sh
development (Nasevicius and Ekker, 2000). We
term the loss of function effects due to morpholinos
a `morphant' phenotype to distinguish this assess-
ment of gene function from that of classical mutant
analyses.
VEGF-A morphant embryos develop with no
overt phenotype during the ®rst day of develop-
ment. The VEGF-A morphant phenotype at 2 days
of embryogenesis, however, consists of an enlarged
pericardium, no circulating red blood cells, a slight
reduction in neural tube and overall body size, and
little or no functioning vasculature (Figure 1B). In a
subset of embryos, red blood cell accumulation can
be noted in the ventral tail (Figure 1C).
We used two separate ¯uorescent assays to assess
vascular function in detail. First, we generated
¯uorescent-labelled red blood cells through the
inactivation of the uroporphyrinogen decarboxylase
(urod; Wang et al., 1998) gene using morpholinos
(Nasevicius and Ekker, 2000). Red blood cells
quantitatively accumulate in the anterior hypochord
(Figure 2B). To analyse the vasculature directly,
we injected ¯uorescein isothiocyanate±Dextran
(FITC±Dextran) into the sinus venosa/cardinal
vein of an anaesthetized 48 h embryo (Figure 2C).
This microangiography assay labels the entire
vasculature of the zebra®sh embryo, including the
yolk sac, heart, head, axial and intersegmental
blood vessels (Weinstein et al., 1995). These
structures are differentially sensitive to VEGF-A
signalling. At high dose injections of VEGF-A
morpholino, the only vasculature detectable in
these animals using this method is found in the
heart and yolk (Figure 2D). The vasculature either
fails to form at all or contains no functioning
connections to the heart in these embryos. To
distinguish between these possibilities we performed
histological analyses on these most severely effected
embryos (Figure 2G±J). Neither dorsal aorta nor
axial vein were noted in the injected embryos
(Figure 2I, J). We also observed a frequent but less
severe phenotypic class of embryos with heart, yolk
and head blood vessels (Figure 2E); no axial or
intersegmental vasculature was observed in these
embryos, however. The least severe phenotypic
classi®cation was represented by embryos with
reduced intersegmental vasculature and normal
heart, yolk, head and axial blood vessels (Fig-
ure 2F). The penetrance of these phenotypic classes
is very dose-dependent (Table 1), consistent with
the strong dose dependence of VEGF-A function in
mouse embryos (Ferrara et al., 1996; Carmeliet
et al., 1996). Heterozygous mouse VEGF-A mutants
showed a reduced dorsal aorta detected by histolo-
gical analysis. Fewer intersegmental blood vessels
were also detected by a tissue-speci®c lacZ expres-
sion (Carmeliet et al., 1996). Lack of the dorsal
aorta was indicated by histological analysis in
homozygous mouse VEGF-A mutants (Carmeliet
et al., 1996), suggesting that the most severe
zebra®sh morphant classes represent a nearly
complete loss of function phenotype. However,
while mouse VEGF-A mutants also display hearts
with underdeveloped myoblasts (Ferrara et al.,
1996; Haigh et al., 2000), the heart in zebra®sh
VEGF-A morphants has an essentially normal
appearance with a slightly enlarged atrium and
ventricle, possibly due to higher cardiac pressure
(histological analysis not shown).
We assessed the phenotypic effects of two VEGF-
A morpholinos of non-overlapping sequence and of
a four-base mismatch sequence (see Materials and
methods) to con®rm the speci®city of targeting
(Table 2). The four-base mismatch morpholino
VEGF-A-D4 demonstrates the sequence-speci®c
nature of the noted effects of the VEGF-A-1
morpholino (Table 2). To test independently for
the speci®city of targeting to the endogenous
VEGF-A gene, we used a second morpholino of
completely independent sequence (VEGF-A-3).
This very potent morpholino caused the same
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dose-dependent reduction of vascular function
(Table 2), pericardial oedema and blood accumula-
tion in the tail (data not shown). The observed
differential ef®cacy might be due to the different
secondary structure of the morpholinos or the
targeted mRNA region. Alternatively, the effect
might be caused by the higher VEGF-A-3 predicted
melting temperature due to higher G/C content
(48%) as compared to VEGF-A-1 (28%). We
conclude that the observed effects are due to
morpholino-based inactivation of VEGF-A gene
function through the speci®c inhibition of VEGF-A
transcript translation.
A number of genes whose mutation results in
cardiovascular defects were observed in the chemi-
cal mutagenesis screens (Stainier et al., 1996; Chen
et al., 1996). None of these mutations strongly
resemble the VEGF-A morphant effects, although
mutant embryos with overlapping phenotypes were
Figure 1. Morphological effects of VEGF-A-1 morpholino injection at 36 h. (A) Wild-type embryo. (B, C) Embryos injected
with 9 ng VEGF-A-1 morpholino. (B) Loss of vasculature, pericardial oedema (black arrowhead) and blood accumulation in
the anterior aorta (black arrow) are prominent (see Table 1 and text). Blood accumulation in tail is also observed (C, black
arrows; see Table 1 and text). Bar=0.2 mm
Table 1. Microangiography analysis of VEGF-A-1 morpholino injection effects at 48 h
Observed phenotypes (frequency, %)
Injected VEGF-A-1 morpholino dose (ng)
369 1 2 1 8
Heart and yolk vasculature only 3t23 t12 1 t43 8 t13 39t1
No axial or intersegmental vasculature 7t42 t12 5 t32 7 t13 29t9
No/reduced intersegmental vasculature 67t57 8 t13 51t23 6 t20 30t6
Normal vasculature 23t10 17t16 3t10 t02 t3
Pericardial oedema 15t23 5 t10 49t25 5 t05 7 t2
Blood accumulation in anterior hypochord 0t01 t15 t33 t08 t2
Blood accumulation in tail 1t12 t21 6 t81 9 t01 9 t7
Total embryo number 110 120 105 106 101
Four experiments were performed with each morpholino dose. The phenotype frequencies in every experiment were averaged and entered into
the table as average frequency. The differences between the average frequency and the individual experiment frequencies were averaged and
entered into the table as a standard error.
VEGF ± a zebra®sh morphant 297
Copyright # 2000 John Wiley & Sons, Ltd. Yeast 2000; 17: 294±301.298 A. Nasevicius, J. Larson and S. C. Ekker
Copyright # 2000 John Wiley & Sons, Ltd. Yeast 2000; 17: 294±301.noted. Multiple loci result in embryos with cardiac
oedema, and a similar accumulation of blood in the
ventral tail ®n was noted due to disorganized
endothelia in the scotch tape (sco) mutation (Chen
et al., 1996). Several mutations with altered circula-
tion were noted (Stainier et al., 1996; Chen et al.,
1996), including gridlock, which encodes for a
bHLH protein that is required only for arterial
development (Weinstein et al., 1995; Stainier et al.,
1996; Zhong et al., 2000). The role of these genes in
VEGF signalling awaits molecular genetic charac-
terization of the remaining loci.
We analysed the expression of two endodermal
vascular markers in VEGF-A morphant embryos.
The transcription factor ¯i-1 is a very early marker
of vascular cell fate speci®cation (Thompson et al.,
1998; Brown et al., 2000). In wild-type 26 h
embryos, ¯i-1 is expressed in the forming dorsal
aorta and axial vein (axial vessels; arrowhead in
Figure 3A) and in the intersegmental vasculature in
overlying somites (Figure 3A, arrows). In embryos
that fail to complete vascular development, only a
subset of the vascular expression pattern of these
genes is altered, contrary to all vasculature sensitiv-
ity to VEGF-A knock-down. No detectable inter-
segmental expression is noted (Figure 3B),
Table 2. Microangiography analysis of VEGF-A-D4 and VEGF-A-3 morpholino injected embryos at 48 h
VEGF-A-D4 morpholino
Injected dose (ng)
36 9 1 2 1 8
Heart and yolk vasculature only 1t10 t02 t33 t03 t0
No axial or intersegmental vasculature 0t00 t00 t00 t00 t0
No/reduced intersegmental vasculature 7t06 t35 t22 2 t11 4 t3
Normal vasculature 92t19 4 t39 3 t37 5 t28 4 t3
Total embryo number 163 116 119 76 73
VEGF-A-3 morpholino 0.5 1.5 3
Heart and yolk vasculature only 0t01 3 t13 27t11
No axial or intersegmental vasculature 0t02 4 t24 40t13
No/reduced intersegmental vasculature 18t83 7 t11 24t14
Normal vasculature 81t22 6 t26 10t10
Total embryo number 32 71 69
Four (VEGF-A-D4 morpholino) or two (VEGF-A-3 morpholino) experiments were performed with each morpholino dose. The phenotype
Figure 2. Visualization of vasculature defects in VEGF-A-1 morphants using microangiography (Weinstein et al., 1995). (A, C,
G, H) Wild-type embryos. (B, D±F, I, J) Embryos injected with 9 ng VEGF-A-1 morpholino. (A, B) 36 h embryos, with red
blood cells (RBC) visualized by the injection of 9 ng urod morpholino. (A) Fluorescing RBC highlight axial vasculature (white
arrowhead), head vasculature (white arrows), yolk sac (yellow arrowhead) and heart (red arrowhead). (B) In the VEGF-A-1
morphant, RBC are localized only to anterior aorta (white arrowheads). (C±F) 48 h embryos with vasculature visualized by
FITC±Dextran injection. (C) Wild-type embryo injected with FITC±Dextran. Axial vasculature (white arrowhead),
intersegmental blood vessels (yellow arrows), head vasculature, yolk sac (yellow arrowhead) and heart (red arrowhead)
are visible. (D) The strongest effect observed upon VEGF-A-1 morpholino injection. The injected FITC±Dextran spreads
throughout the yolk sac and heart only. Head, axial and intersegmental blood vessels are not visible. (E) Moderate VEGF-A-1
morpholino injection effect. The injected FITC±Dextran highlights yolk sac, heart and head blood vessels only. (F) Weak
VEGF-A-1 morpholino injection effect. No/few intersegmental blood vessels are observed (yellow arrows). Yolk sac, heart,
head vasculature and axial blood vessels appear to be normal. In panels A±F, axial vessels are indicated by white arrowhead,
intersegmental blood vessels are indicated by yellow arrows, head vasculature is indicated by white arrows, heart is indicated
by red arrowhead, and yolk sac is indicated by yellow arrowhead. (G±J) Mid-trunk cross-sections of strongly effected 48 h
VEGF morphant embryos. (G, I) Fluorescence images of sectioned embryos with FITC±Dextran visualized vasculature. Dorsal
aorta (white arrow) and axial vein (white arrowhead) are indicated by FITC±Dextran ¯uorescence in the wild-type embryo
(G), while the vasculature is absent in the injected embryo (I; white arrow and arrowhead indicate where dorsal aorta and
axial vein would normally be). (H, J) Haematoxylin±eosin-stained sections shown in (G) and (I), respectively. White arrows
indicate present (H) or absent (J) dorsal aorta. White arrowheads indicate present (H) or absent (J) axial vein. Bars=0.2 mm
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lar endoderm sensitivity to VEGF signalling
(Table 1). The cells are either not properly speci®ed
or fail to migrate during formation of the interseg-
mental vessels. Similar results were obtained upon
analysis of expression of the VEGF receptor, ¯k-1.
¯k-1 transcript distribution is very similar to that of
¯i-1 in the trunk and tail of wild-type embryos
(Figure 3C). In VEGF-A morphant embryos, inter-
segmental but not axial expression is absent
(Figure 3D). A signi®cant reduction in ¯k-1 gene
expression was noted in mouse embryos with no
VEGF-A activity (Carmeliet et al., 1996). A less
extreme lack of ¯k-1-expressing cells in the inter-
segmental vasculature was also observed in the
mouse with the partial and conditional VEGF-A
knock-out (Haigh et al., 2000). The results in
Figure 3 represent work with 9 ng VEGF-A-1
injection-dose embryos; 18 ng injection-dose
embryos display the same speci®c loss of expression
only in the intersegmental regions for both ¯i-1 and
¯k-1 (data not shown).
The distinct responsiveness of the expression of
the endothelial marker ¯i-1 in intersegmental vessels
to VEGF-A signalling demonstrates a dual role for
VEGF during vascular development. First, VEGF-A
is required for proper axial vessel formation but not
for initial axial vessel patterning. Second, VEGF-A
is required for intersegmental vessel cell speci®ca-
tion or migration and, presumably, for subsequent
vascular formation. The lack of a requirement for
VEGF signalling for ¯k-1 expression is consistent
with previous observations of paracrine modes of
VEGF signalling (reviewed in Ferrara, 1999). The
expression of the VEGF receptor ¯k-1 is, however,
VEGF-dependent during intersegmental vasculari-
zation. This latter observation suggests a possible
autoregulatory loop, functioning during vasculo-
genesis of the intersegmental vessels.
The strong conservation of VEGF function from
®sh to mammals implicates this as a fundamental
vertebrate biological pathway. The use of morpho-
lino-based gene targeting represents a new tool in
the genetic repertoire of vertebrate biologists and,
Figure 3. Comparative expression of ¯i-1 and ¯k-1 in 26 h wild-type and VEGF±A-1 morpholino-injected zebra®sh embryos
visualized by in situ hybridization. Anterior is to the left. (A, C) Wild-type. (B, D) Embryos injected with 9 ng VEGF-A-1
morpholino. (A, B) ¯i-1 expression. Arrows in (A) depict staining in intersegmental vessels. Arrowheads in (A, B) depict
staining in the axial vessels. The VEGF-A-1 morphant in (B) lacks ¯i-1 expression in the intersegmental vessels. (C, D) ¯k-1
expression. Arrows in (C) depict staining in intersegmental vessels. Arrowheads in (C, D) depict staining in axial vessels. The
VEGF-A-1 morphant in (D) lacks ¯k-1 expression in the intersegmental vessels
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zebra®sh, will be extremely powerful in the elabora-
tion of gene function for similarly conserved
developmental processes. This method will help
further elaborate the role of VEGF during embryo-
genesis through the targeted knockdown of other
players in this signalling pathway in this outstand-
ing model system.
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